Cyclometalated Iridium(III) Complexes as Mitochondria-targeting Photosensitizers against Cisplatin-resistant Cells

Photochem Photobiol. 2022 Jan;98(1):85-91. doi: 10.1111/php.13404. Epub 2021 Mar 4.

Abstract

Four iridium (III) complexes Ir1-Ir4 were synthesized and characterized. Possessing high singlet oxygen production ability and specific mitochondria-localization, Ir1 was developed as a mitochondria-targeting photosensitizer. Ir1 exhibited strong phototoxicity against cancer cell line A549 and its corresponding cisplatin-resistant one A549R. In contrast, Ir1 showed low cytotoxicity toward normal cell HLF. This selectivity resulted from the different uptake amount. With 405 nm irradiation, Ir1 induced mitochondria-mediated cell death in A549R cells, achieving the overcome of drug-resistant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / metabolism
  • Antineoplastic Agents* / pharmacology
  • Apoptosis
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Coordination Complexes* / pharmacology
  • Iridium / metabolism
  • Iridium / pharmacology
  • Mitochondria / metabolism
  • Photosensitizing Agents / metabolism
  • Photosensitizing Agents / pharmacology
  • Reactive Oxygen Species / metabolism

Substances

  • Antineoplastic Agents
  • Coordination Complexes
  • Photosensitizing Agents
  • Reactive Oxygen Species
  • Iridium
  • Cisplatin